Comparison of the absolute numbers of human cells in the BM of NOD/SCID-β2m−/− and NOD/SCID-β2m−/−-3/GM/SF mice at varying times after transplantation
. | . | No. of positive mice/no. of mice injected . | Percentage of human CD45/71+ cells in BM aspirates (range delimited by ± SEM)* . | . | . | . | |||
---|---|---|---|---|---|---|---|---|---|
Patient no. . | Recipient genotype . | . | 3 wk . | 5-7 wk . | 8-12 wk . | 15-23 wk . | |||
1 | β2m−/−-3/GM/SF | 1/2 | 0.47 | 0.75 | 32, 15† | 42, 16† | |||
1 | β2m−/− | 0/2 | — | — | — | — | |||
3 | β2m−/−-3/GM/SF | 2/2 | 4.8, 0.6 | 0.25, 0.5 | — | — | |||
3 | β2m−/− | 5/7 | 3.3 (1.2-9.2) | 0.4 (0.3-0.5) | — | — | |||
7 | β2m−/−-3/GM/SF | 3/6 | 149, 1.4, 4 | 0.25, 0.3, 0.25 | — | — | |||
7 | β2m−/− | 7/7 | 3 (1-11) | 1 (0.5-2.3) | — | — | |||
8 | β2m−/−-3/GM/SF | 1/1 | — | — | 0.4 | 0.8 | |||
8 | β2m−/− | 0/1 | — | — | — | — | |||
9 | β2m−/−-3/GM/SF | 1/1 | 3 | 36 | — | — | |||
9 | β2m−/− | 1/1 | 85 | 10 | — | — | |||
10 | β2m−/−-3/GM/SF | 2/2 | 24, 2‡ | 387, 77‡ | 134, 16‡ | 138, 12‡ | |||
10 | β2m−/− | 7/7 | 1 (0.7-1.5) | 2.6 (1.6-4.4) | 1.8 (1.1-2.9) | 2.8 (1.5-5.2) | |||
11 | β2m−/−-3/GM/SF | 1/2 | 8 | 4 | 0.28 | 0.4-0.8 | |||
11 | β2m−/− | 0/2 | — | — | — | — | |||
Normal lin− BM | β2m−/−-3/GM/SF | 6/6 | 3.7 (2.3-6.1) | 56 (37-83)‡ | 12 (8.5-16) | 2.8 (1.2-6.4) | |||
Normal lin− BM | β2m−/− | 5/6 | 0.6 (0.3-1) | 3.6 (1.9-6.9) | 4.1 (2.2-7.6) | 0.8 (0.5-1.4) |
. | . | No. of positive mice/no. of mice injected . | Percentage of human CD45/71+ cells in BM aspirates (range delimited by ± SEM)* . | . | . | . | |||
---|---|---|---|---|---|---|---|---|---|
Patient no. . | Recipient genotype . | . | 3 wk . | 5-7 wk . | 8-12 wk . | 15-23 wk . | |||
1 | β2m−/−-3/GM/SF | 1/2 | 0.47 | 0.75 | 32, 15† | 42, 16† | |||
1 | β2m−/− | 0/2 | — | — | — | — | |||
3 | β2m−/−-3/GM/SF | 2/2 | 4.8, 0.6 | 0.25, 0.5 | — | — | |||
3 | β2m−/− | 5/7 | 3.3 (1.2-9.2) | 0.4 (0.3-0.5) | — | — | |||
7 | β2m−/−-3/GM/SF | 3/6 | 149, 1.4, 4 | 0.25, 0.3, 0.25 | — | — | |||
7 | β2m−/− | 7/7 | 3 (1-11) | 1 (0.5-2.3) | — | — | |||
8 | β2m−/−-3/GM/SF | 1/1 | — | — | 0.4 | 0.8 | |||
8 | β2m−/− | 0/1 | — | — | — | — | |||
9 | β2m−/−-3/GM/SF | 1/1 | 3 | 36 | — | — | |||
9 | β2m−/− | 1/1 | 85 | 10 | — | — | |||
10 | β2m−/−-3/GM/SF | 2/2 | 24, 2‡ | 387, 77‡ | 134, 16‡ | 138, 12‡ | |||
10 | β2m−/− | 7/7 | 1 (0.7-1.5) | 2.6 (1.6-4.4) | 1.8 (1.1-2.9) | 2.8 (1.5-5.2) | |||
11 | β2m−/−-3/GM/SF | 1/2 | 8 | 4 | 0.28 | 0.4-0.8 | |||
11 | β2m−/− | 0/2 | — | — | — | — | |||
Normal lin− BM | β2m−/−-3/GM/SF | 6/6 | 3.7 (2.3-6.1) | 56 (37-83)‡ | 12 (8.5-16) | 2.8 (1.2-6.4) | |||
Normal lin− BM | β2m−/− | 5/6 | 0.6 (0.3-1) | 3.6 (1.9-6.9) | 4.1 (2.2-7.6) | 0.8 (0.5-1.4) |
β2m−/−-3/GM/SF indicates NOD/SCID-β2m−/−-3/GM/SF ; β2m−/−, NOD/SCID-β2m−/−; and —, no data available.
Values shown are the derived total numbers of human CD45/71+ cells (×105) assuming that 2 femurs and 2 tibiae represent 25% of all mouse BM cells and that the total cellularity of these 4 long bones was as measured in a large set of similarly treated mice.
Data are from a single mouse assessed at different times in the interval shown (the second mouse died 8 weeks after transplantation).
Values in the 2 different types of recipient are significantly different P <. 05.